Tevogen Bio (NASDAQ:TVGN) Shares Down 6.4% – Here’s Why

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) dropped 6.4% during trading on Wednesday . The company traded as low as $0.3084 and last traded at $0.3172. Approximately 486,137 shares were traded during trading, a decline of 8% from the average daily volume of 529,920 shares. The stock had previously closed at $0.3390.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TVGN. Weiss Ratings restated a “sell (e+)” rating on shares of Tevogen Bio in a report on Wednesday, January 21st. D. Boral Capital dropped their price target on shares of Tevogen Bio from $10.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, November 20th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Tevogen Bio has an average rating of “Hold” and an average target price of $5.00.

Tevogen Bio Stock Performance

The firm has a 50 day moving average of $0.38 and a two-hundred day moving average of $0.67. The stock has a market cap of $63.02 million, a P/E ratio of -1.67 and a beta of -0.79.

Tevogen Bio (NASDAQ:TVGN) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03.

Institutional Trading of Tevogen Bio

A hedge fund recently raised its stake in Tevogen Bio stock. Bridgeway Capital Management LLC raised its stake in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) by 66.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 82,500 shares of the company’s stock after purchasing an additional 33,000 shares during the quarter. Bridgeway Capital Management LLC’s holdings in Tevogen Bio were worth $65,000 as of its most recent filing with the SEC.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.